Liquid biopsy breakthrough: FDA okays Guardant360 CDx to match patients to Eli Lilly’s Inluriyo

Guardant Health, Inc. (NASDAQ: GH) confirmed that the U.S. Food and Drug Administration has granted approval for its Guardant360 CDx liquid biopsy assay to be used as a companion diagnostic for Eli Lilly and Company’s (NYSE: LLY) newly approved oral selective estrogen receptor degrader, Inluriyo (imlunestrant). This approval covers adults with estrogen receptor–positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer harboring ESR1 mutations, following progression on at least one prior endocrine therapy.

The news marks a strategic expansion of blood-based genomic profiling in breast cancer, embedding Guardant Health’s platform into the care pathway for patients whose tumors have developed resistance to standard endocrine regimens.

Why is the FDA’s approval of Guardant360 CDx as a companion diagnostic such a critical development in breast cancer treatment?

This approval means oncologists can now rely on a simple blood draw to detect actionable ESR1 mutations that emerge as resistance mechanisms in hormone receptor-positive disease. Traditionally, tissue biopsies were required, but these procedures are often invasive, painful, and sometimes inconclusive in advanced cancer. By authorizing Guardant360 CDx, the FDA has validated liquid biopsy as a clinically reliable alternative that provides faster turnaround times and a more comprehensive view of tumor heterogeneity.

The ESR1 mutation is highly prevalent in advanced ER-positive, HER2-negative breast cancer, affecting roughly 40 percent of patients. Detecting these mutations is vital because they directly influence treatment decisions, particularly the switch to novel endocrine therapies such as Inluriyo.

How does the companion diagnostic link to the clinical data supporting Inluriyo’s approval?

The companion diagnostic authorization stems from results of the Phase 3 EMBER-3 trial. In this pivotal study, Inluriyo demonstrated a 38 percent reduction in the risk of disease progression or death compared with standard endocrine therapies. Median progression-free survival improved to 5.5 months with Inluriyo versus 3.8 months in the control group. These results underscore the value of testing for ESR1 mutations at the point of therapeutic resistance, ensuring that eligible patients are rapidly matched to the drug that offers the best chance of delaying disease progression.

The synergy between Guardant360 CDx and Inluriyo reinforces a test-to-treat paradigm that is gaining traction across oncology. With FDA backing, the diagnostic and the therapy are formally linked, providing oncologists with a clear clinical algorithm: identify ESR1 mutations using Guardant360 CDx, and transition patients to Inluriyo.

What makes liquid biopsy an important tool compared with traditional tissue-based testing?

Liquid biopsy platforms such as Guardant360 CDx analyze circulating tumor DNA in plasma, enabling comprehensive genomic profiling through next-generation sequencing. This method not only reduces the invasiveness of cancer testing but also reflects real-time tumor evolution. Tumors in advanced breast cancer are often heterogeneous and metastasize to multiple sites, meaning that a single tissue biopsy may not capture the complete molecular picture.

Blood-based assays address this challenge by sampling tumor DNA shed into the bloodstream, giving oncologists insights into mutation profiles as they change under treatment pressure. This is particularly relevant for ESR1 mutations, which commonly emerge after aromatase inhibitor therapy and can dictate the need for switching to a SERD such as Inluriyo.

How does this approval affect Guardant Health’s competitive positioning in precision oncology?

Guardant Health has steadily expanded its regulatory portfolio since Guardant360 CDx was first cleared for detecting EGFR mutations in non-small cell lung cancer. Over the years, the test has gained multiple companion diagnostic claims, making it one of the most broadly validated liquid biopsy platforms in the U.S.

By securing another FDA-approved breast cancer indication tied to a high-profile Eli Lilly drug, Guardant Health strengthens its moat against competing diagnostic players. Companion diagnostics drive not just test adoption but also commercial synergies, as pharmaceutical companies integrate the assays into their drug launch strategies. For Guardant, each new approval creates durable demand because it embeds the test within drug labeling, payer coverage frameworks, and clinical guidelines.

This latest nod also builds on the earlier approval of Guardant360 CDx for elacestrant, marketed as Orserdu, another SERD used in ESR1-mutated breast cancer. Taken together, Guardant has positioned its test as the standard for ESR1 detection, making it a critical partner in the broader endocrine therapy landscape.

How did the stock market react to Guardant Health’s latest FDA milestone, and what does sentiment suggest for investors?

Shares of Guardant Health (NASDAQ: GH) traded around $61.01 on Monday afternoon, reflecting cautious optimism from investors who see regulatory approvals as incremental drivers of testing volume and revenue growth. The modest uptick signals that the market values FDA companion diagnostic claims but is awaiting clarity on adoption rates, payer reimbursement, and real-world test demand.

Eli Lilly and Company (NYSE: LLY), which closed near $723.51, saw limited immediate impact given its massive size and diversified pipeline. While Inluriyo’s approval is positive for its oncology franchise, it represents only a fraction of Lilly’s market capitalization.

Investor sentiment around Guardant Health can be characterized as “cautiously constructive.” Institutional investors are likely to hold or modestly accumulate positions until payer policies and uptake data confirm the revenue upside. Buy ratings will hinge on evidence of faster clinical adoption and coverage determinations, while sell cases would likely emerge if reimbursement lags or physician uptake is slower than expected.

What hurdles remain in reimbursement and adoption before Guardant360 CDx becomes routine in clinical practice?

Regulatory approval is only the first step toward clinical normalization. For Guardant360 CDx to become routine, payer adoption must follow. In the U.S., Medicare already covers broad genomic profiling in metastatic cancer, but new indications often require specific coding updates and coverage policy adjustments. Commercial insurers will evaluate cost-effectiveness before fully embracing the test.

On the ground, community oncologists will need clear workflows to integrate plasma ESR1 testing into patient management. Practical factors such as turnaround time, prior authorization, and reimbursement will strongly influence uptake. Guardant Health’s messaging around “expanded access through a simple blood draw” resonates with clinicians, but execution will determine whether the promise translates into practice.

Globally, adoption may be slower. Regulatory harmonization, payer willingness, and regional practice patterns vary widely. In Europe and Asia, tissue biopsy is still the gold standard, and liquid biopsy often enters as a complementary tool before gaining equal footing.

What does this mean for Eli Lilly’s breast cancer pipeline, and how might testing demand evolve?

For Eli Lilly, Inluriyo is a critical addition to its oncology arsenal, complementing its existing therapies and setting the stage for combination strategies. Ongoing trials are exploring Inluriyo with CDK4/6 inhibitors and in earlier-line settings, which could expand its commercial reach. If future data supports adjuvant use, testing for ESR1 mutations could shift earlier in the treatment pathway, driving further demand for Guardant360 CDx.

This development reflects a broader oncology trend: drugs are increasingly being approved alongside precise molecular entry criteria and companion diagnostics. The test-to-treat approach aligns clinical efficacy with payer priorities, ensuring that only patients most likely to benefit gain access to expensive therapies.

How does this fit into the larger story of liquid biopsy adoption across oncology?

Guardant360 CDx has become one of the most visible proofs of concept for liquid biopsy in real-world practice. Starting from lung cancer, the test has expanded into multiple tumor types, each approval reinforcing the idea that blood-based assays can reliably guide treatment.

For ESR1-mutated breast cancer, the clinical rationale is particularly strong. Resistance evolves dynamically, making it impractical to depend solely on tissue biopsies. Liquid biopsy offers a repeatable, less invasive, and scalable alternative that aligns with the practical realities of oncology care.

The regulatory accumulation of multiple approvals for Guardant360 CDx signals to physicians, payers, and patients that liquid biopsy is no longer experimental but an increasingly standard feature of modern oncology.

What should stakeholders watch in the months ahead as Guardant360 CDx expands its clinical footprint?

For Guardant Health, the next two quarters will be critical in demonstrating adoption. Test order volumes, turnaround times, and payer coverage decisions will be the key metrics investors track. For clinicians, the immediate challenge is embedding ESR1 testing into their workflows and ensuring patients receive results quickly enough to guide treatment transitions.

Patients, meanwhile, stand to benefit from fewer invasive procedures and faster access to therapies like Inluriyo, which has been priced at approximately $22,500 per 28-day cycle in the United States. That price point ensures payer scrutiny, but also underlines why validated companion diagnostics are essential to match therapies to the right population. Overall, this approval is not just another regulatory milestone—it is a signal of where oncology is heading. As liquid biopsy continues to gain ground, Guardant Health’s regulatory track record gives it a clear edge in shaping h